Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning reported that the company has hired Dr. M. Scott Alexander as a medical director.
Marijuana Investing
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo.
India Globalization Capital, Inc. (NYSE: IGC) Launches Pharmaceutical Cannabinoid Pipeline Websites
India Globalization Capital (NYSE American: IGC) this morning announced the launching of two new websites.
SinglePoint, Inc. (SING) Inks LOI Formalizing Joint Venture with Smart Cannabis Corp. (SCNA)
SinglePoint (OTC: SING) and Smart Cannabis (OTC: SCNA) have signed a Letter of Intent (“LOI”) to formalize a joint venture relationship.
Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management
One pioneering biopharmaceutical company, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), has triggered a paradigm shift in discovering potential breakthrough cannabinoid-based therapies. .-
Aphria enters into supplier agreement with Shoppers Drug Mart
Aphria Inc. (TSX: APH and US OTC: APHQF) today announced that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart. -
Purified Cannabinoids Open New Opportunities in Pain Management
As consumer acceptance continues to propel demand to unprecedented levels, companies such as InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) are making waves in the advancement of cannabinoid compounds as a medical solution in pain management and other indications.-
Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Cannevert Subsidiary Inks Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico
Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), has signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico.
SinglePoint, Inc. (SING) Enters Joint Venture Agreement with Smart Cannabis Corp. (SCNA)
SinglePoint (OTC: SING) this morning said it has entered a joint venture relationship with Smart Cannabis Corp. (OTC: SCNA) to license and market Smart Cannabis’ SMART app.
Spectrum Cannabis Denmark Announces Forty Thousand Square Metre Medical Cannabis Facility in Odense
Hi-tech Greenhouse Positions Spectrum Cannabis as European Cannabis Leader & Odense as Major European Medical Cannabis Centre-
Marijuana Company of America, Inc. (MCOA) Further Strengthens Positioning in the Cannabis and Industrial Hemp CBD Markets
Marijuana Company of America (OTC: MCOA) has established a commanding presence in the cannabis and industrial hemp cannabidiol (“CBD”) markets, as well as the related services supply chain, creating an umbrella over a diverse portfolio of cannabis- and hemp-based companies.
Aurora Cannabis Completes Larssen and H2 Biopharma Acquisitions
Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that, further to its press releases of November 23, 2017, the Company has completed the acquisitions of Larssen Ltd, a globally leading greenhouse engineering and design consultancy, and that of H2 Biopharma, a late-stage ACMPR applicant based in Quebec.-
Aurora Cannabis Increases Ownership Interest in Radient Technologies
Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Radient Technologies Inc. ("Radient) (TSX-V: RTI) today announced that further to the investor rights agreement between both companies, as announced on November 6, 2017, Aurora will make a further investment in Radient for a total of $12 million
Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Provides 2018 Strategy Update Regarding Growth Plans
Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) this morning provided an update regarding its growth plans for 2018.
Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study. Data Help Clarify Protocol Design for Planned ZYN002 Phase 2 Trial in Epilepsy -